This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Jazz must face US antitrust claims over Xyrem, federal judge rules

( September 15, 2025, 22:31 GMT | Official Statement) -- MLex Summary: Jazz Pharmaceuticals must face US antitrust counterclaims filed by Avadel, a judge ruled. District Judge Gregory B. Williams found that there is a genuine dispute of material fact regarding when the Food and Drug Administration would have approved Avadel's application for the drug Lumryz but for Jazz's listing of a patent regarding the drug Xyrem the Orange Book, denying a motion for judgment. Jazz originally filed patent infringement claims against Avadel. See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections